Keros Therapeutics said on Wednesday it would voluntarily halt testing of an experimental blood pressure treatment due to ...

LEXINGTON, Mass., Jan. 15, 2025 (GLOBE NEWSWIRE) -- (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage ...

A month after halting dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial hypertension ...

Taken together with Keros’ recent pivot away from obesity, the termination of its pulmonary arterial hypertension study could ...

The action affects the TROPOS trial of cibotacept (KER-012), an activin signalling inhibitor that works in a similar way to ...

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) have been assigned a consensus recommendation of “Moderate ...

Shares in Keros Therapeutics fell sharply Wednesday morning after it said it halted trials of its treatment for pulmonary hypertension after finding adverse health effects in patients trialing the ...

Providing additional update on the Phase 2 TROPOS trial on Wednesday, biopharmaceutical company Keros Therapeutics, Inc. (KROS) ...

Keros Therapeutics (KROS) announced that it has voluntarily halted all dosing in the TROPOS trial, a Phase 2 clinical trial of cibotercept in ...

Keros Therapeutics has halted the dosing of its treatment for pulmonary hypertension due to adverse health effects discovered during trials. The clinical-stage biopharmaceutical company said Wednesday ...

Shares of Keros Therapeutics (KROS) plunged nearly 20% in premarket trading on Wednesday, poised to hit an all-time low after ...

Investing.com -- Shares of Keros Therapeutics (NASDAQ:KROS) tumbled 17% after the company announced a voluntary halt on all dosing in the TROPOS trial, which is evaluating cibotercept (KER-012) in ...